MannKind Zukünftiges Wachstum
Future Kriterienprüfungen 4/6
MannKind wird ein Gewinn- und Umsatzwachstum von 37.8% bzw. 14.5% pro Jahr prognostiziert, während der Gewinn pro Aktie um 36.8% pro Jahr wachsen soll.
Wichtige Informationen
39.4%
Wachstumsrate der Gewinne
38.6%
EPS-Wachstumsrate
Biotechs Gewinnwachstum | 28.2% |
Wachstumsrate der Einnahmen | 14.0% |
Zukünftige Eigenkapitalrendite | n/a |
Analystenabdeckung | Low |
Zuletzt aktualisiert | 09 Sep 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
MannKind Corporation's (NASDAQ:MNKD) Share Price Boosted 28% But Its Business Prospects Need A Lift Too
Sep 18Is There An Opportunity With MannKind Corporation's (NASDAQ:MNKD) 49% Undervaluation?
Jul 17MannKind Outperforms As Tyvaso DPI Captures Market Share
May 15This Just In: Analysts Are Boosting Their MannKind Corporation (NASDAQ:MNKD) Outlook for This Year
Mar 03MannKind Corporation (NASDAQ:MNKD) Surges 35% Yet Its Low P/S Is No Reason For Excitement
Mar 02MannKind's Tyvaso DPI Royalty Deal Signals Undervaluation
Feb 15MannKind Corporation's (NASDAQ:MNKD) Price Is Right But Growth Is Lacking
Jan 03Revenues Working Against MannKind Corporation's (NASDAQ:MNKD) Share Price
May 15MannKind Corporation's (NASDAQ:MNKD) Intrinsic Value Is Potentially 68% Above Its Share Price
Jan 27Mannkind Corporation: Ready For Your Biotech Portfolio
Sep 01New Forecasts: Here's What Analysts Think The Future Holds For MannKind Corporation (NASDAQ:MNKD)
Aug 19MannKind down 2% after Q2 2022 bottom line miss; however, net loss narrowed
Aug 09MannKind: What Do Pfizer, Sanofi, And MannKind Have In Common?
Feb 25MannKind: A Promising Player In The Inhalable Insulin Market
Feb 08US$6.17: That's What Analysts Think MannKind Corporation (NASDAQ:MNKD) Is Worth After Its Latest Results
Aug 14Lytham Partners Summer 2021 Investor Conference
Jun 14MannKind (MNKD) Investor Presentation - Slideshow
Jun 04MannKind reduces debt by $49.5M and restructures remaining obligations
Apr 26Did Business Growth Power MannKind's (NASDAQ:MNKD) Share Price Gain of 293%?
Feb 22MannKind to co-promote Thyquidity
Dec 17MannKind (MNKD) earns $12.5M milestone under licensing deal for treprostinil
Nov 20Gewinn- und Umsatzwachstumsprognosen
Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
---|---|---|---|---|---|
12/31/2026 | 395 | 116 | N/A | 46 | 4 |
12/31/2025 | 337 | 71 | N/A | 45 | 4 |
12/31/2024 | 289 | 27 | N/A | 42 | 3 |
6/30/2024 | 248 | 12 | 18 | 41 | N/A |
3/31/2024 | 225 | 8 | 3 | 40 | N/A |
12/31/2023 | 199 | -12 | -8 | 34 | N/A |
9/30/2023 | 177 | -31 | -32 | 10 | N/A |
6/30/2023 | 158 | -47 | -57 | -27 | N/A |
3/31/2023 | 128 | -71 | -72 | -61 | N/A |
12/31/2022 | 100 | -87 | -88 | -81 | N/A |
9/30/2022 | 76 | -98 | -98 | -91 | N/A |
6/30/2022 | 66 | -88 | -89 | -78 | N/A |
3/31/2022 | 70 | -94 | -83 | -67 | N/A |
12/31/2021 | 75 | -81 | -73 | -62 | N/A |
9/30/2021 | 81 | -79 | -60 | -49 | N/A |
6/30/2021 | 75 | -86 | -54 | -47 | N/A |
3/31/2021 | 66 | -61 | -35 | -30 | N/A |
12/31/2020 | 65 | -57 | -33 | -28 | N/A |
9/30/2020 | 63 | -45 | -34 | -33 | N/A |
6/30/2020 | 62 | -44 | -73 | -72 | N/A |
3/31/2020 | 62 | -46 | -91 | -88 | N/A |
12/31/2019 | 63 | -52 | -91 | -88 | N/A |
9/30/2019 | 63 | -47 | -61 | -58 | N/A |
6/30/2019 | 53 | -61 | -22 | -20 | N/A |
3/31/2019 | 42 | -71 | -28 | -28 | N/A |
12/31/2018 | 28 | -87 | -38 | -38 | N/A |
9/30/2018 | 16 | -110 | -93 | -93 | N/A |
6/30/2018 | 13 | -119 | -102 | -102 | N/A |
3/31/2018 | 12 | -131 | N/A | -95 | N/A |
12/31/2017 | 11 | -117 | N/A | -65 | N/A |
9/30/2017 | 20 | -31 | N/A | -48 | N/A |
6/30/2017 | 180 | 129 | N/A | -47 | N/A |
3/31/2017 | 178 | 134 | N/A | -39 | N/A |
12/31/2016 | 175 | 126 | N/A | -78 | N/A |
9/30/2016 | 162 | -205 | N/A | -88 | N/A |
6/30/2016 | N/A | -364 | N/A | -85 | N/A |
3/31/2016 | N/A | -363 | N/A | -91 | N/A |
12/31/2015 | N/A | -368 | N/A | -57 | N/A |
9/30/2015 | N/A | -128 | N/A | -70 | N/A |
6/30/2015 | N/A | -133 | N/A | 50 | N/A |
3/31/2015 | N/A | -177 | N/A | 44 | N/A |
12/31/2014 | N/A | -198 | N/A | 4 | N/A |
9/30/2014 | N/A | -216 | N/A | 6 | N/A |
6/30/2014 | N/A | -230 | N/A | -127 | N/A |
3/31/2014 | N/A | -203 | N/A | -134 | N/A |
12/31/2013 | N/A | -191 | N/A | -129 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: MNKDDas prognostizierte Gewinnwachstum (37.8% pro Jahr) liegt über der Sparquote (2.4%).
Ertrag vs. Markt: MNKDDie Erträge des Unternehmens (37.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (14.8% pro Jahr).
Hohe Wachstumserträge: MNKDEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.
Einnahmen vs. Markt: MNKDDie Einnahmen des Unternehmens (14.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).
Hohe Wachstumseinnahmen: MNKDDie Einnahmen des Unternehmens (14.5% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von MNKD in 3 Jahren voraussichtlich hoch sein wird